1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin.

Diheptanoyllecithin is a non-hydrolyzable analog.

DCAF1-BRD9 PROTAC DBr-1 potently degrades BRD9 with a DC50 of 90 nM but only weakly affected BRD7 protein levels. DBr-1 provides an alternative strategy to tackle intrinsic resistance to VHL-degrader.

Compound 38 (NNMT inhibitor) is a potent uncompetitive inhibitors of nicotinamide n-methyltransferase (NNMT). Compound 38 inhibits NNMT in both in vitro biochemical and cell-based assays with IC50 = 42 nM and 38 nM, respectively. Compound 38 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties.

ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.

a LRRK2 degrader for the treatment of PD and PSP

a TYK2 degrader for multiple immune-mediated diseases.

an AR degrader for the treatment of mCRPC.

BMS-986365 (CC-94676) is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. BMS-986365 (CC-94676) is about 100-fold more potent than enzalutamide (ENZ) at inhibiting androgen-stimulated transcription of AR target genes, and 10 to 120-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro.

an ER degrader for the treatment of BC.

a BTK degrader for the treatment of B-cell malignancies.

a BTK degrader for the treatment of B-cell malignancies.

a mutant and wild-type NTRK degrader for the treatment of solid tumors.

a STAT3 degrader for the treatment of PTCL.

a MDM2 degrader for the treatment of r/r high grade myeloid malignancies and solid tumors.

a KRASG12D degrader for the treatment of solid tumors.

a BRD9 degrader for treating synovial sarcoma.

a topical AR degrader for the treatment of acne vulgaris.

20-HETE inhibitor-1 (comp 83) is a 20-HETE formation inhibitor